QUOTIENT-SCIENCES
25.8.2021 14:02:08 CEST | Business Wire | Press release
Quotient Sciences , the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The investment will significantly expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over the next three years.
Quotient acquired the Alnwick facility from Arcinova in February 2021 to expand its service portfolio to include drug substance, drug product and clinical testing capabilities all under one organization. The acquisition enables Quotient to support customers with an “end to end” offering from candidate selection through commercial product launch. The multimillion-pound investment will repurpose a 1,500 square-meter footprint and incorporate additional equipment and technologies — significantly expanding the number of new molecules developed each year.
Additional equipment, featuring the latest advances in digital control and data capture, will ensure robust transfer from laboratory to multi-kilo scale production. Plus, processing equipment with new developments in modular continuous technology will maximize responsiveness and agility for manufacturing processes. These updates, combined with a five-fold increase in scale, will increase Quotient’s capacity by over 10 times for developing complex medicines.
“Following our integration into Quotient Sciences earlier in the year, it is tremendously exciting to see the Alnwick facility continue to expand capabilities as we move into larger scale and commercial manufacturing,” said Quotient Sciences SVP Candidate Development Services Roger Kilburn . “Science and agility are at the core of Quotient Sciences, and our team strives to innovate and develop smarter approaches to process R&D for our customers and drive the adoption of continuous processing technologies.”
The Alnwick facility employs 170 people across a range of scientific disciplines, and this investment will create a variety of new jobs. Quotient continues to grow and was recently presented an award for “Most Inspirational North East (U.K.) Science Employer,” from STEM Learning, as part of the STEM Ambassadors program.
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005188/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corpay Cross-Border Named the Official FX Partner of Newcastle United21.10.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into a multi-year agreement with Newcastle United to become their Official Foreign Exchange (FX) Partner. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Newcastle United’s day-to-day business operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “We’re thrilled to be named the Official FX Partner of Newcastle United, one of the Premier League’s most iconic and ambitious clubs,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership further strengthens Corpay’s position as the trusted corporate payments and currency risk management provider of choice across the Premier League. We loo
Insight Named an OpenAI Advanced Partner to Accelerate Midmarket Enterprise AI Adoption21.10.2026 14:28:00 CEST | Press release
As an OpenAI Advanced Partner, Insight will accelerate ChatGPT Enterprise, Codex, and AI adoption at scale through its Radius™ and Rapid AI offerings Insight Enterprises (NASDAQ: NSIT) today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network, reinforcing Insight's position as a provider of AI solutions for midmarket and lower-enterprise organisations seeking to accelerate AI adoption. As part of the expanded relationship, Insight will work with OpenAI to help organisations build, deploy and scale AI solutions responsibly and effectively. The expanded relationship reflects Insight's experience helping organisations successfully deploy and scale AI. “Insight has built a repeatable approach that connects technology, process transformation, and workforce adoption so clients can move from pilots to production and results faster,” said Jack Azagury, Insight President and CEO. “As an OpenAI Advanced Partner, we can help more organisations deploy AI r
Amadeus Explores Next-Generation Flight Search with NVIDIA21.10.2026 14:00:00 CEST | Press release
Amadeus and NVIDIA have been collaborating to explore how accelerated computing and travel-specific AI could support faster, more scalable and more efficient flight search. Building on this work, the companies have now signed a Memorandum of Understanding (MoU) to deepen their collaboration and accelerate further exploration. As AI assistants increasingly search on behalf of travelers, they are changing both the volume and complexity of demand placed on travel technology. Amadeus, in collaboration with NVIDIA, have already conducted initial technical assessments and benchmarking activities, on the NVIDIA Hopper and Blackwell platform, NVIDIA's accelerated computing architectures designed for AI and high-performance computing workloads, to better understand how accelerated computing could support large-scale travel shopping workloads. Through the MoU, Amadeus and NVIDIA will continue this collaboration, with aims to deliver faster, more scalable and more efficient flight search as AI-po
TreviPay Expands Pay by Invoice Availability for Walmart Business Customers21.10.2026 14:00:00 CEST | Press release
The general availability gives eligible organizations more flexibility with net 30-day terms, a dedicated business line of credit and streamlined reconciliation TreviPay, a global B2B payments infrastructure partner, today announced the general availability of Pay By Invoice for eligible Walmart Business customers. Following an initial pilot, the expanded availability gives more organizations a new way to manage purchasing and payments online and in Walmart stores. Walmart Business Pay By Invoice provides net 30-day terms, a dedicated business line of credit and detailed invoicing built into the Walmart Business purchasing experience. Powered by TreviPay, Walmart Business Pay By Invoice is designed to give organizations greater flexibility in how they manage business purchases and payments. Eligible customers can get what they need and pay on net 30-day terms, helping them preserve cash flow for other priorities while keeping operations moving. Purchasing controls and payment reconcili
Global Network for the Advancement of Metabolic Psychiatry (MetPsy) Launches with $20 Million Investment in Clinical Care, Education and Research at McLean Hospital21.10.2026 14:00:00 CEST | Press release
Baszucki Group funding awarded to McLean Hospital to establish a flagship clinical and research center, and jointly to McLean and MH² for medical education and training initiatives Baszucki Group today announced the launch of the Global Network for the Advancement of Metabolic Psychiatry (MetPsy), uniting researchers and clinicians worldwide to advance evidence-based practice in metabolic psychiatry through clinical care, education, and research. The launch is accompanied by a new $20 million grant from Baszucki Group to build a clinical and research center at McLean Hospital, a member of Mass General Brigham, creating the infrastructure to deliver metabolic approaches to psychiatric care at scale. The grant also supports medical education and training initiatives co-led by MH², a clinical practice, training and education hub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021217733/en/ MetPsy, a global network for metabo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom